Lymphoma, Leukemia, Precision Oncology
We want to advance the understanding of molecular and genetic lesions in the pathogenesis of blood cancer subtypes and use this understanding to exploit it therapeutically in clinical care.
Over the last years, my group has focused on understanding the governing principles underlying drug response and developed practice changing use of novel drugs in blood cancer. We use high‐throughput drug screening and omics‐profiling to leverage precision medicine in blood cancer with a strong focus on lymphoid malignancies. We build on this strong research focus to develop a next generation of precision medicine tools to improve patient outcome and care. We strive to solve key questions regarding optimal treatment of a wide range of tumors within a unique network of researchers.Publications